JNJ - Johnson & Johnson
144.47
| Index: | DJIA, S&P 500 | P/E: | 23.88 | EPS (ttm): | 6.05 | Insider Own: | 0.12% | Shs Outstand: | 2.41B | Perf Week: | -1.47% |
| Market Cap: | 349.99B | Forward P/E: | 13.66 | EPS next Y: | 10.58 | Insider Trans: | -0.16% | Shs Float: | 2.40B | Perf Month: | -5.64% |
| Income(ttm): | 14.68B | PEG: | 3.98 | EPS next Q: | 2.02 | Inst Own: | 72.73% | Short Float: | 0.77% | Perf Quarter: | -11.49% |
| Revenue(ttm): | 87.69B | P/S: | 3.99 | EPS this Y: | 0.36% | Inst Trans: | 0.63% | Short Ratio: | 2.58 | Perf Half Y: | -3.12% |
| Book/sh: | 29.14 | P/B: | 4.96 | EPS next Y: | 6.24% | ROA: | 8.58% | Short Interest: | 18.54M | Perf Year: | -5.74% |
| Cash/sh: | 8.38 | P/C: | 17.24 | EPS next 5Y: | 6.00% | ROE: | 20.89% | 52W Range: | 143.13 - 168.85 | Perf YTD: | -7.83% |
| Dividend Est.: | 4.64 (3.21%) | P/FCF: | 16.87 | EPS past 5Y: | -0.27% | ROI: | 14.47% | 52W High: | -14.44% | Beta: | 0.51 |
| Dividend TTM: | 4.91 (3.40%) | Quick Ratio: | 0.79 | Sales past 5Y: | 1.31% | Gross Margin: | 68.67% | 52W Low: | 0.94% | ATR (14): | 2.35 |
| Dividend Ex-Date: | Nov 26, 2024 | Current Ratio: | 1.03 | EPS Y/Y TTM: | 15.10% | Oper. Margin: | 24.60% | RSI (14): | 32.06 | Volatility: | 1.86% 1.48% |
| Employees: | 131900 | Debt/Eq: | 0.51 | Sales Y/Y TTM: | -8.03% | Profit Margin: | 16.75% | Recom: | 2.17 | Target Price: | 176.21 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.45 | EPS Q/Q: | -43.91% | Payout: | 84.93% | Rel Volume: | 2.45 | Prev Close: | 143.58 |
| Sales Surprise: | 1.35% | EPS Surprise: | 9.68% | Sales Q/Q: | 5.27% | Earnings: | Oct 15 BMO | Avg Volume: | 7.19M | Price: | 144.47 |
| SMA20: | -3.48% | SMA50: | -6.96% | SMA200: | -6.74% | Undervalued: 21.97% | Volume: | 17,607,210 | Change: | 0.62% | |
Graham Classic formula value: 111.37
(P/E=8 * 1g) Min value: 76.06
(current P/E * 2g) Max value: 194.92
Average value: 127.45
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.